<List><item><source>MED</source><extId>30987401</extId><pmcid>PMC6479480</pmcid><annotations><annotation><prefix>Clinicaltrials.gov: </prefix><exact>NCT00658619</exact><postfix>) involving 119 part</postfix><tags><tag><name>NCT00658619</name><uri>http://identifiers.org/clinicaltrials/NCT00658619</uri></tag></tags><id>http://europepmc.org/articles/PMC6479480#europepmc-a65a8cc91785f6c3dbeb96554eeb2724</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ients is currently underway (Beacon, </prefix><exact>NCT02087085</exact><postfix>). </postfix><tags><tag><name>NCT02087085</name><uri>http://identifiers.org/clinicaltrials/NCT02087085</uri></tag></tags><id>http://europepmc.org/articles/PMC6479480#europepmc-bcf22bebf24e10ddc0759224dafc9517</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>e 2 clinical trial (</prefix><exact>NCT01229215</exact><postfix>) investigated the e</postfix><tags><tag><name>NCT01229215</name><uri>http://identifiers.org/clinicaltrials/NCT01229215</uri></tag></tags><id>http://europepmc.org/articles/PMC6479480#europepmc-5f2d8de3d238a76f4998a617c7256a36</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> trial for dry AMD (</prefix><exact>NCT00950638</exact><postfix>), started in 2009, </postfix><tags><tag><name>NCT00950638</name><uri>http://identifiers.org/clinicaltrials/NCT00950638</uri></tag></tags><id>http://europepmc.org/articles/PMC6479480#europepmc-82b9579e2f18344da7aed4864afc8256</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>The phase 2a trial (</prefix><exact>NCT03362190</exact><postfix>) evaluated the safe</postfix><tags><tag><name>NCT03362190</name><uri>http://identifiers.org/clinicaltrials/NCT03362190</uri></tag></tags><id>http://europepmc.org/articles/PMC6479480#europepmc-0117cae0b83f1baaeef2480b67888e09</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ipants with GA secondary to dry AMD (</prefix><exact>NCT02686658</exact><postfix>). </postfix><tags><tag><name>NCT02686658</name><uri>http://identifiers.org/clinicaltrials/NCT02686658</uri></tag></tags><id>http://europepmc.org/articles/PMC6479480#europepmc-68d8af0a7e1f0f06142add3ccc459c9f</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>e I clinical trial (</prefix><exact>NCT00473928</exact><postfix>) in wet AMD patient</postfix><tags><tag><name>NCT00473928</name><uri>http://identifiers.org/clinicaltrials/NCT00473928</uri></tag></tags><id>http://europepmc.org/articles/PMC6479480#europepmc-4208f9434cb6c208dc48aa75768343b0</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ase 1 and 2 trials (</prefix><exact>NCT00473928</exact><postfix>, NCT02503332), and </postfix><tags><tag><name>NCT00473928</name><uri>http://identifiers.org/clinicaltrials/NCT00473928</uri></tag></tags><id>http://europepmc.org/articles/PMC6479480#europepmc-d7439dbe1bc209d9c8bd2cc9c54a3291</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>rials (NCT00473928, </prefix><exact>NCT02503332</exact><postfix>), and it showed no </postfix><tags><tag><name>NCT02503332</name><uri>http://identifiers.org/clinicaltrials/NCT02503332</uri></tag></tags><id>http://europepmc.org/articles/PMC6479480#europepmc-da0e4f6f2a64b9e0108ae9ce0188be9b</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ls, Oaks and Derby (</prefix><exact>NCT03525613</exact><postfix>-NCT03525600), are b</postfix><tags><tag><name>NCT03525613</name><uri>http://identifiers.org/clinicaltrials/NCT03525613</uri></tag></tags><id>http://europepmc.org/articles/PMC6479480#europepmc-5cbe146c1a5f00d2682f6f1269f71e86</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> Derby (NCT03525613-</prefix><exact>NCT03525600</exact><postfix>), are being initiat</postfix><tags><tag><name>NCT03525600</name><uri>http://identifiers.org/clinicaltrials/NCT03525600</uri></tag></tags><id>http://europepmc.org/articles/PMC6479480#europepmc-8d575080165980f78ad500a6f8b1ef19</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ow doses of LFG316 (</prefix><exact>NCT01527500</exact><postfix>), 158 participants </postfix><tags><tag><name>NCT01527500</name><uri>http://identifiers.org/clinicaltrials/NCT01527500</uri></tag></tags><id>http://europepmc.org/articles/PMC6479480#europepmc-4efd208e1a2a2d610231dd8eac9c01b3</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>